- Home
- ICCH vs KRON Comparison
ICCH vs KRON Comparison
Compare ICCH & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCH
- KRON
- Stock Information
- Founded
- ICCH 1950
- KRON 2017
- Country
- ICCH United States
- KRON United States
- Employees
- ICCH N/A
- KRON N/A
- Industry
- ICCH Property-Casualty Insurers
- KRON Medicinal Chemicals and Botanical Products
- Sector
- ICCH Finance
- KRON Health Care
- Exchange
- ICCH Nasdaq
- KRON Nasdaq
- Market Cap
- ICCH 68.8M
- KRON 57.8M
- IPO Year
- ICCH 2017
- KRON 2020
- Fundamental
- Price
- ICCH $23.86
- KRON $0.96
- Analyst Decision
- ICCH
- KRON Buy
- Analyst Count
- ICCH 0
- KRON 3
- Target Price
- ICCH N/A
- KRON $1.63
- AVG Volume (30 Days)
- ICCH 7.8K
- KRON 379.1K
- Earning Date
- ICCH 11-04-2024
- KRON 11-13-2024
- Dividend Yield
- ICCH N/A
- KRON N/A
- EPS Growth
- ICCH 42.86
- KRON N/A
- EPS
- ICCH 2.16
- KRON N/A
- Revenue
- ICCH $92,541,259.00
- KRON $9,864,000.00
- Revenue This Year
- ICCH N/A
- KRON $62.21
- Revenue Next Year
- ICCH N/A
- KRON N/A
- P/E Ratio
- ICCH $11.05
- KRON N/A
- Revenue Growth
- ICCH 14.09
- KRON 146.48
- 52 Week Low
- ICCH $14.78
- KRON $0.69
- 52 Week High
- ICCH $23.95
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- ICCH 74.33
- KRON 50.33
- Support Level
- ICCH $23.23
- KRON $0.91
- Resistance Level
- ICCH $23.35
- KRON $1.01
- Average True Range (ATR)
- ICCH 0.10
- KRON 0.06
- MACD
- ICCH 0.04
- KRON -0.01
- Stochastic Oscillator
- ICCH 89.77
- KRON 32.94
About ICCH ICC Holdings Inc.
ICC Holdings Inc is a specialty insurance carrier underwriting commercial multi-peril, liquor liability, worker's compensation, and umbrella liability coverages for the food and beverage industry. The company markets its products through a network of independent agents in Colorado, Illinois, Indiana, Iowa, Kansas, Minnesota, Missouri, Pennsylvania, Ohio, and Wisconsin.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.